Giorgio Baldari

1.8k citations

50 papers · 1.3k indexed · h-index 17

Cardiology and Cardiovascular Medicine top 2%
Nephrology top 1%
Nutrition and Dietetics top 5%
Endocrinology, Diabetes and Metabolism top 5%
Pulmonary and Respiratory Medicine top 10%

Co-authors: Stefano Bianchi Roberto Bigazzi Vito M. Campese Duccio Baldari V. M. Campese Livia Ruffini Andrea Natali Eleuterio Ferrannini
Topics: Radiopharmaceutical Chemistry and Applications (10 papers)Blood Pressure and Hypertension Studies (8 papers)Chronic Kidney Disease and Diabetes (7 papers)
Cited by: Nephrology Cardiology and Cardiovascular Medicine Nutrition and Dietetics
Journals: SHILAP Revista de lepidopterologíaBlood The American Journal of Medicine
Partner nations: Italy United States Netherlands

In The Last Decade

Giorgio Baldari

46 papers receiving 1.3k citations

Peers

Countries citing papers authored by Giorgio Baldari

Since Specialization

Citations

This map shows the geographic impact of Giorgio Baldari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giorgio Baldari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giorgio Baldari more than expected).

Fields of papers citing papers by Giorgio Baldari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giorgio Baldari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giorgio Baldari. The network helps show where Giorgio Baldari may publish in the future.

Co-authorship network of co-authors of Giorgio Baldari

This figure shows the co-authorship network connecting the top 25 collaborators of Giorgio Baldari. A scholar is included among the top collaborators of Giorgio Baldari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giorgio Baldari. Giorgio Baldari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Automated Scale-Down Development and Optimization of [68Ga]Ga-DOTA-EMP-100 for Non-Invasive PET Imaging and Targeted Radioligand Therapy of c-MET Overactivation in Cancer 2025 ·SHILAP Revista de lepidopterología ·(unknown),Anna R. Gagliardi,(unknown),(unknown),Giorgio Baldari,Alex Gibson,(unknown),Livia Ruffini	0
2	Establishment and validation of an alternative automated synthesis of [68Ga]Ga-DOTA-Siglec-9 in an independent laboratory for clinical use 2025 ·EJNMMI Radiopharmacy and Chemistry ·(unknown),(unknown),Anna R. Gagliardi,(unknown),Stefano Bruno,Anne Roivainen,Sarita Forsbäck,Giorgio Baldari,(unknown),Livia Ruffini	0
3	Validation of a radiosynthesis method and a novel quality control system for [68 Ga]Ga-MAA: is TLC enough to assess radiopharmaceutical quality? 2024 ·EJNMMI Radiopharmacy and Chemistry ·(unknown),Stefano Bruno,Annalisa Bianchera,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Giorgio Baldari,Ruggero Bettini,Livia Ruffini	0
4	Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit 2023 ·Chinese Clinical Oncology ·Umberto Maestroni,Davide Campobasso,(unknown),Anna Acampora,(unknown),Francesco Ziglioli,(unknown),Giorgio Baldari,(unknown),Donatello Gasparro,Stefania Ferretti,Enrico Maria Silini,Livia Ruffini	3
5	High Prognostic Value of 68Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry 2023 ·Diagnostics ·Donatello Gasparro,(unknown),Enrico Maria Silini,(unknown),Giorgio Baldari,(unknown),Tiziano Graziani,Nicoletta Campanini,Umberto Maestroni,Livia Ruffini	7
6	Scale down and optimized automated production of [68Ga]68Ga-DOTA-ECL1i PET tracer targeting CCR2 expression 2023 ·EJNMMI Radiopharmacy and Chemistry ·(unknown),(unknown),Giorgio Baldari,Livia Ruffini	4
7	Validation of the HPLC Analytical Method for the Determination of Chemical and Radiochemical Purity of Ga-68-DOTATATE 2023 ·Indian Journal of Nuclear Medicine ·(unknown),(unknown),(unknown),(unknown),Giorgio Baldari,Livia Ruffini	1
8	Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [68Ga]Ga-NODAGA-Exendin-4 Produced by a Fully Automated Method 2022 ·Molecules ·(unknown),(unknown),Marti Boss,Martin Gotthardt,(unknown),Giorgio Baldari,Claudia Silva,Riccardo C. Bonadonna,Livia Ruffini	9
9	A Specific HPLC Method to Determine Residual HEPES in [68Ga]Ga-Radiopharmaceuticals: Development and Validation 2022 ·Molecules ·(unknown),(unknown),Giorgio Baldari,Cláudia Silva,Livia Ruffini	11
10	Proceedings of the World Molecular Imaging Congress 2021, October 5-8, 2021: Late-Breaking Abstracts 2021 ·Molecular Imaging and Biology ·(unknown),(unknown),(unknown),Marti Boss,Martin Gotthardt,(unknown),Giorgio Baldari,Claudia Silva,Riccardo C. Bonadonna,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	3
11	Feasibility of a Scale-down Production of [68Ga]Ga-NODAGA-Exendin-4in a Hospital Based Radiopharmacy 2021 ·Current Radiopharmaceuticals ·(unknown),(unknown),(unknown),Giorgio Baldari,Barbara Janota,Riccardo C. Bonadonna,Livia Ruffini	7
12	[68Ga]Ga-PSMA-HBED-CC PET/CT demonstrates to be superior to ceCT in detecting early treatment response in metastatic clear cell renal cell carcinoma 2021 ·European Journal of Nuclear Medicine and Molecular Imaging ·Priscilla Guglielmo,Donatello Gasparro,(unknown),Giorgio Baldari,(unknown),(unknown),(unknown),Umberto Maestroni,Livia Ruffini	2
13	A Rapid and Specific HPLC Method to Determine Chemical and Radiochemical Purity of [68>Ga]Ga-DOTA-Pentixafor (PET) Tracer: Development and Validation 2020 ·Current Radiopharmaceuticals ·(unknown),(unknown),(unknown),Giorgio Baldari,Cláudia Silva,Livia Ruffini	5
14	Validation of quality control parameters of cassette-based gallium-68-DOTA-Tyr3-octreotate synthesis 2020 ·Indian Journal of Nuclear Medicine ·(unknown),(unknown),(unknown),Giorgio Baldari,Livia Ruffini	5
15	Dipsogenic Factors Operating in Chronic Uremics on Maintenance Hemodialysis 1994 ·The Nephron journals/Nephron journals ·S. Giovannetti,(unknown),Adamasco Cupisti,E. Morelli,Bruno Agostini,(unknown),P Gazzetti,Lara Dani,M. Aloisi,Alessandro Antonelli,Giorgio Baldari,(unknown),(unknown),Roberto Palla	23
16	Lone-Term Effects of a Converting Enzyme Inhibitor and a Calcium Channel Blocker on Urinary Albumin Excretion in Patients With Essential Hypertension 1993 ·American Journal of Hypertension ·Roberto Bigazzi,Stefano Bianchi,Duccio Baldari,(unknown),Giorgio Baldari,Vito M. Campese	31
17	Prevalence of Microalbuminuria in a Large Population of Patients with Mild to Moderate Essential Hypertension 1992 ·The Nephron journals/Nephron journals ·Roberto Bigazzi,Stefano Bianchi,Vito M. Campese,Giorgio Baldari	123
18	High-Permeable Membranes and Hypersensitivity-Like Reactions: Role of Dialysis Fluid Contamination 1990 ·Blood Purification ·Roberto Bigazzi,(unknown),Giorgio Baldari	24
19	Effects of enalapril on urinary protein excretion of essential and renal parenchymal hypertensive patients. Comparison between colorimetric and radioimmunological methods. 1988 ·PubMed ·(unknown),Roberto Bigazzi,(unknown),(unknown),(unknown),(unknown),(unknown),Stefano Bianchi,(unknown),Giorgio Baldari	1
20	Thyroid Function in Patients with Chronic Renal Failure Submitted to Hemofiltration 1984 ·Blood Purification ·Roberto Bigazzi,Fabio Monzani,E Martino,(unknown),(unknown),Alessio Mazzoni,L. Grasso,Giorgio Baldari,Aldo Pinchera	1

About Giorgio Baldari

Giorgio Baldari is a scholar working on Nephrology, Radiology, Nuclear Medicine and Imaging and Oncology, having authored 50 papers that have together received 1.3k indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (10 papers), Blood Pressure and Hypertension Studies (8 papers) and Chronic Kidney Disease and Diabetes (7 papers). The work is most often cited by research in Nephrology (461 citations), Cardiology and Cardiovascular Medicine (804 citations) and Nutrition and Dietetics (266 citations). Giorgio Baldari has collaborated with scholars based in Italy, United States and Netherlands. Frequent co-authors include Stefano Bianchi, Roberto Bigazzi, Vito M. Campese, Duccio Baldari, V. M. Campese, Livia Ruffini, Andrea Natali, Eleuterio Ferrannini, Ele Ferrannini and Alfredo Quiñones Galvan. Their work appears in journals such as SHILAP Revista de lepidopterología, Blood and The American Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact